JP2019518741A5 - - Google Patents

Download PDF

Info

Publication number
JP2019518741A5
JP2019518741A5 JP2018559885A JP2018559885A JP2019518741A5 JP 2019518741 A5 JP2019518741 A5 JP 2019518741A5 JP 2018559885 A JP2018559885 A JP 2018559885A JP 2018559885 A JP2018559885 A JP 2018559885A JP 2019518741 A5 JP2019518741 A5 JP 2019518741A5
Authority
JP
Japan
Prior art keywords
cancer
inhibitor
alkyl
pharmaceutical composition
perfluoroalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018559885A
Other languages
English (en)
Japanese (ja)
Other versions
JP7013388B2 (ja
JP2019518741A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/032200 external-priority patent/WO2017197140A1/en
Publication of JP2019518741A publication Critical patent/JP2019518741A/ja
Publication of JP2019518741A5 publication Critical patent/JP2019518741A5/ja
Priority to JP2021167100A priority Critical patent/JP7190548B2/ja
Application granted granted Critical
Publication of JP7013388B2 publication Critical patent/JP7013388B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018559885A 2016-05-11 2017-05-11 Ｈｄａｃ阻害剤とｐｄ－ｌ１阻害剤との組み合わせ療法 Active JP7013388B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021167100A JP7190548B2 (ja) 2016-05-11 2021-10-12 Ｈｄａｃ阻害剤とｐｄ－ｌ１阻害剤との組み合わせ療法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662335056P 2016-05-11 2016-05-11
US62/335,056 2016-05-11
PCT/US2017/032200 WO2017197140A1 (en) 2016-05-11 2017-05-11 Combination therapies of hdac inhibitors and pd-l1 inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021167100A Division JP7190548B2 (ja) 2016-05-11 2021-10-12 Ｈｄａｃ阻害剤とｐｄ－ｌ１阻害剤との組み合わせ療法

Publications (3)

Publication Number Publication Date
JP2019518741A JP2019518741A (ja) 2019-07-04
JP2019518741A5 true JP2019518741A5 (OSRAM) 2020-07-16
JP7013388B2 JP7013388B2 (ja) 2022-01-31

Family

ID=60267123

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018559885A Active JP7013388B2 (ja) 2016-05-11 2017-05-11 Ｈｄａｃ阻害剤とｐｄ－ｌ１阻害剤との組み合わせ療法
JP2021167100A Active JP7190548B2 (ja) 2016-05-11 2021-10-12 Ｈｄａｃ阻害剤とｐｄ－ｌ１阻害剤との組み合わせ療法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021167100A Active JP7190548B2 (ja) 2016-05-11 2021-10-12 Ｈｄａｃ阻害剤とｐｄ－ｌ１阻害剤との組み合わせ療法

Country Status (15)

Country Link
US (3) US10385131B2 (OSRAM)
EP (1) EP3454843A4 (OSRAM)
JP (2) JP7013388B2 (OSRAM)
KR (2) KR20220123742A (OSRAM)
CN (1) CN109640985A (OSRAM)
AU (2) AU2017264857B2 (OSRAM)
BR (1) BR112018073328A2 (OSRAM)
CA (1) CA3023546A1 (OSRAM)
EA (1) EA201892581A1 (OSRAM)
IL (1) IL262808B2 (OSRAM)
MA (1) MA44990A (OSRAM)
MX (2) MX390986B (OSRAM)
NZ (1) NZ748058A (OSRAM)
TW (1) TWI794171B (OSRAM)
WO (1) WO2017197140A1 (OSRAM)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2712655B1 (en) 2011-04-28 2019-12-18 The Broad Institute, Inc. Inhibitors of histone deacetylase
WO2014018979A1 (en) 2012-07-27 2014-01-30 The Broad Institute, Inc. Inhibitors of histone deacetylase
BR112017018234A2 (pt) 2015-02-26 2018-04-17 Merck Patent Gmbh inibidores de pd-1 / pd-l1 para o tratamento de câncer
CA2978942A1 (en) 2015-03-13 2016-09-22 Cytomx Therapeutics, Inc. Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof
KR102712880B1 (ko) 2015-06-16 2024-10-02 메르크 파텐트 게엠베하 Pd-l1 길항제 조합 치료
EP3400009A2 (en) * 2016-01-05 2018-11-14 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Combination of histone deacetylase inhibitor and immunotherapy
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
TWI794171B (zh) * 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
GB2567093A (en) 2016-07-15 2019-04-03 Viracta Therapeutics Inc Histone deacetylase inhibitors for use in immunotherapy
MX2019003755A (es) * 2016-10-06 2019-08-12 Pfizer Regimen de dosificacion de avelumab para el tratamiento de cancer.
MX394242B (es) 2017-01-11 2025-03-24 Rodin Therapeutics Inc Inhibidores biciclicos de histona desacetilasa
KR20200016899A (ko) 2017-06-01 2020-02-17 싸이톰스 테라퓨틱스, 인크. 활성화가능 항-pdl1 항체, 및 이의 이용 방법
JOP20200024A1 (ar) 2017-08-04 2020-02-02 Bayer Ag مركبات ثنائي هيدروكساديازينون
WO2019025554A1 (en) 2017-08-04 2019-02-07 Bayer Aktiengesellschaft 6-PHENYL-4,5-DIHYDROPYRIDAZIN-3 (2H) -ONE DERIVATIVES AS INHIBITORS OF PDE3A AND PDE3B FOR THE TREATMENT OF CANCER
MX2020001484A (es) 2017-08-07 2020-08-20 Rodin Therapeutics Inc Inhibidores bicíclicos de la histona desacetilasa.
TR201900059A2 (tr) 2018-01-05 2019-07-22 Gnt Biotech & Medicals Corp Bi̇r farmasöti̇k kombi̇nasyon ve tümör mi̇kroortaminin ve i̇mmünoterapi̇ni̇n regülasyonu i̇çi̇n yöntem
JP2021511293A (ja) * 2018-01-12 2021-05-06 ビラクタ セラピューティクス，インク． 細胞免疫療法で使用されるエピジェネティック修飾因子
US12128018B2 (en) 2018-01-12 2024-10-29 KDAc Therapeutics, Inc. Combination of a selective histone deacetylase 3 (HDAC3) inhibitor and an immunotherapy agent for the treatment of cancer
EP3820859B1 (en) * 2018-07-13 2024-03-20 Alkermes, Inc. Inhibitors of histone deacetylase
TWI781356B (zh) * 2018-11-20 2022-10-21 大陸商深圳微芯生物科技股份有限公司 西達本胺的應用
CN113348165B (zh) 2019-02-01 2024-06-25 拜耳股份有限公司 用于治疗过度增殖性疾病的1,2,4-三嗪-3(2h)-酮化合物
US20220175850A1 (en) * 2019-04-01 2022-06-09 Houn Simon Hsia Compositions and methods for cancer therapy
KR20210028339A (ko) * 2019-09-04 2021-03-12 크리스탈지노믹스(주) Hdac 저해제와 항 pd-1 항체 또는 항 pd-l1 항체를 포함하는 약학 조성물
US11878009B2 (en) * 2019-09-10 2024-01-23 Great Novel Therapeutics Biotech & Medicals Corporation Anticancer combination of chidamide and celecoxib salts
TW202114659A (zh) * 2019-10-02 2021-04-16 德商４Ｓｃ製藥公司 用於癌症治療之含ｈｄａｃ抑制劑、ｃｔｌａ—４抑制劑及ｐｄ—１抑制劑或ｐｄ—ｌ１抑制劑之組合
US20220395494A1 (en) * 2019-11-05 2022-12-15 Health Research, Inc. Combination therapy for cancer
WO2021129616A1 (zh) * 2019-12-23 2021-07-01 信达生物制药(苏州)有限公司 抗pd-1抗体和组蛋白去乙酰化酶抑制剂的药物组合及其用途、使用方法
AU2021333655A1 (en) * 2020-08-25 2023-05-04 Huyabio International, Llc Methods and compositions for genetic modulation of tumor microenvironments

Family Cites Families (538)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH627446A5 (fr) 1978-01-17 1982-01-15 Debiopharm Sa Nouveaux derives de la benzamide.
GB8302483D0 (en) 1983-01-29 1983-03-02 Beecham Group Plc Compounds
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US4870074A (en) 1986-04-30 1989-09-26 Dainippon Pharmaceutical Co., Ltd. Substituted benzamide derivatives, for enhancing gastrointestinal motility
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
ATE356869T1 (de) 1990-01-12 2007-04-15 Amgen Fremont Inc Bildung von xenogenen antikörpern
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
CA2089661C (en) 1990-08-29 2007-04-03 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
JP2529912B2 (ja) 1990-10-16 1996-09-04 帝国化学産業株式会社 ベンズアミド誘導体
US5395832A (en) 1991-02-15 1995-03-07 Hokuriku Seiyaku Co., Ltd. Benzamide derivatives
TW219935B (OSRAM) 1991-12-25 1994-02-01 Mitsubishi Chemicals Co Ltd
US5236931A (en) 1992-03-26 1993-08-17 A. H. Robins Company, Incorporated 2-substituted benzamide and benzoate derivatives of 3-aminoquinuclidine and 3-quinuclidinol
US5610052A (en) 1992-08-26 1997-03-11 Ribozyme Pharmaceuticals Inc. Enzymatic RNA with activity to ras
WO1995029891A1 (en) 1994-04-28 1995-11-09 Yamanouchi Pharmaceutical Co., Ltd. N-(3-pyrrolidinyl)benzamide derivative
US5783568A (en) 1994-06-10 1998-07-21 Sugen, Inc. Methods for treating cancer and other cell proliferative diseases
JPH0823980A (ja) 1994-07-15 1996-01-30 Terumo Corp 脳神経細胞のアポトーシス時に発現する核レセプターおよびそれをコードする核レセプター遺伝子
ATE390933T1 (de) 1995-04-27 2008-04-15 Amgen Fremont Inc Aus immunisierten xenomäusen stammende menschliche antikörper gegen il-8
AU2466895A (en) 1995-04-28 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5958792A (en) 1995-06-07 1999-09-28 Chiron Corporation Combinatorial libraries of substrate-bound cyclic organic compounds
GB9525620D0 (en) 1995-12-15 1996-02-14 Glaxo Group Ltd Chemical compounds
EP0827742A1 (en) 1996-09-04 1998-03-11 Vrije Universiteit Brussel Use of histone deacetylase inhibitors for treating fribosis or cirrhosis
GB9821483D0 (en) 1998-10-03 1998-11-25 Glaxo Group Ltd Chemical compounds
US6174905B1 (en) 1996-09-30 2001-01-16 Mitsui Chemicals, Inc. Cell differentiation inducer
JP3354090B2 (ja) 1996-09-30 2002-12-09 シエーリング アクチエンゲゼルシャフト 分化誘導剤
GB9625145D0 (en) 1996-12-03 1997-01-22 Smithkline Beecham Plc Novel compounds
EP2314625B1 (en) 1996-12-03 2014-05-07 Amgen Fremont Inc. Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom
JPH10330254A (ja) 1997-04-01 1998-12-15 Kissei Pharmaceut Co Ltd 翼状片の進行および術後の再発抑制剤
US6444849B1 (en) 1997-06-25 2002-09-03 Mitsubishi Chemical Corporation Amide derivatives
AU737018B2 (en) 1997-07-25 2001-08-09 Tsumura & Co. Pyridylacrylamide derivatives and nephritis remedies and TGF-beta inhibitors containing the same
ES2375931T3 (es) 1997-12-05 2012-03-07 The Scripps Research Institute Humanización de anticuerpo murino.
US6140351A (en) 1997-12-19 2000-10-31 Berlex Laboratories, Inc. Ortho-anthranilamide derivatives as anti-coagulants
US6673827B1 (en) 1999-06-29 2004-01-06 The Uab Research Foundation Methods of treating fungal infections with inhibitors of NAD synthetase enzyme
JP4405602B2 (ja) 1998-04-16 2010-01-27 バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト ヒストン脱アセチル化酵素阻害剤
TR200003355T2 (tr) 1998-05-15 2001-03-21 Astrazeneca Ab Sitokinin sebep olduğu hastalıkların tedavisinde benzamid türevlerinin kullanılması
EP1140903B1 (en) 1998-12-23 2004-08-04 Eli Lilly And Company Aromatic amides
JP2000256194A (ja) 1999-01-06 2000-09-19 Mitsui Chemicals Inc 核内レセプタ作動薬およびその効果増強剤
JP2002536432A (ja) 1999-02-11 2002-10-29 シーオーアール セラピューティクス インコーポレイテッド 第Ｘａ因子の阻害剤
SK13132001A3 (sk) 1999-03-17 2002-02-05 Astrazeneca Ab Amidové deriváty, spôsob ich prípravy, farmaceutická kompozícia, ktorá ich obsahuje, a ich použitie
AU3757600A (en) 1999-03-19 2000-10-09 Vertex Pharmaceuticals Incorporated Oral low dose butyrate compositions
JP2001081031A (ja) 1999-08-30 2001-03-27 Schering Ag 溶解性および経口吸収性を改善したベンズアミド誘導体含有製剤
BR0014254A (pt) 1999-09-08 2002-08-27 Sloan Kettering Inst Cancer Nova classe de agentes de citodiferenciação e inibidores de desacetilase de histona, e métodos de uso dos mesmos
JP4360660B2 (ja) 1999-11-09 2009-11-11 三井化学株式会社 モノアシルフェニレンジアミン誘導体の精製法
EP1252305A2 (en) 1999-12-08 2002-10-30 Genset Full-length human cdnas encoding potentially secreted proteins
TWI284639B (en) 2000-01-24 2007-08-01 Shionogi & Co A compound having thrombopoietin receptor agonistic effect
ATE489360T1 (de) 2000-03-24 2010-12-15 Methylgene Inc Inhibitoren der histon-deacetylase
US7005439B2 (en) 2000-06-20 2006-02-28 Astrazeneca Ab Compounds
EP1170008A1 (en) 2000-07-07 2002-01-09 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Valproic acid and derivatives thereof as histone deacetylase inhibitors
EP1335898B1 (en) 2000-09-29 2005-11-23 TopoTarget UK Limited Carbamic acid compounds comprising an amide linkage as hdac inhibitors
US20020103192A1 (en) 2000-10-26 2002-08-01 Curtin Michael L. Inhibitors of histone deacetylase
US6905669B2 (en) 2001-04-24 2005-06-14 Supergen, Inc. Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
US6897220B2 (en) 2001-09-14 2005-05-24 Methylgene, Inc. Inhibitors of histone deacetylase
US6706686B2 (en) 2001-09-27 2004-03-16 The Regents Of The University Of Colorado Inhibition of histone deacetylase as a treatment for cardiac hypertrophy
TW200304374A (en) 2001-11-30 2003-10-01 Smithkline Beecham Plc Novel compounds
US7993626B2 (en) 2007-01-11 2011-08-09 Immunomedics, Inc. Methods and compositions for F-18 labeling of proteins, peptides and other molecules
CN1681489A (zh) 2002-07-17 2005-10-12 蒂坦药物股份有限公司 增加抗肿瘤活性的化疗药物的联用
US20050215601A1 (en) 2002-09-25 2005-09-29 Santen Pharmaceutical Co., Ltd. Therapeutic agent for rheumatic disease comprising benzamide derivative as active ingredient
US8163896B1 (en) 2002-11-14 2012-04-24 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory genes and uses thereof
US7790867B2 (en) 2002-12-05 2010-09-07 Rosetta Genomics Inc. Vaccinia virus-related nucleic acids and microRNA
US20050054647A1 (en) 2002-12-27 2005-03-10 Detlev Schuppan New pharmaceutical combination
US7244751B2 (en) 2003-02-14 2007-07-17 Shenzhen Chipscreen Biosciences Ltd. Histone deacetylase inhibitors of novel benzamide derivatives with potent differentiation and anti-proliferation activity
WO2005002626A2 (en) 2003-04-25 2005-01-13 Gilead Sciences, Inc. Therapeutic phosphonate compounds
PE20050206A1 (es) 2003-05-26 2005-03-26 Schering Ag Composicion farmaceutica que contiene un inhibidor de histona deacetilasa
MY142655A (en) 2003-06-12 2010-12-15 Euro Celtique Sa Therapeutic agents useful for treating pain
US9005613B2 (en) 2003-06-16 2015-04-14 Immunomedics, Inc. Anti-mucin antibodies for early detection and treatment of pancreatic cancer
CN1284772C (zh) 2003-07-04 2006-11-15 深圳微芯生物科技有限责任公司 具有分化和抗增殖活性的苯甲酰胺类组蛋白去乙酰化酶抑制剂及其药用制剂
CA2536042A1 (en) 2003-11-10 2005-06-02 Angiotech International Ag Medical implants and anti-scarring agents
US20130189364A1 (en) 2004-07-09 2013-07-25 Robert Sabin Compositions and methods of potentiating adjuvant pharmaceuticals targeting latent viral infections
NZ589276A (en) 2005-02-03 2012-06-29 Topotarget Uk Ltd Combination therapies using hdac inhibitors and erlotinib (tarceva)
US9707302B2 (en) 2013-07-23 2017-07-18 Immunomedics, Inc. Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
JP5265204B2 (ja) 2005-03-04 2013-08-14 ライフスキャン・インコーポレイテッド 成人膵臓由来間質細胞
DK2161336T4 (en) 2005-05-09 2017-04-24 Ono Pharmaceutical Co Human monoclonal antibodies for programmed death 1 (PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapies
US20090280153A1 (en) 2005-05-10 2009-11-12 Angiotech International Ag electrical devices, anti-scarring agents, and therapeutic compositions
WO2006135479A2 (en) 2005-05-10 2006-12-21 Angiotech International Ag Anti-scarring agents, therapeutic compositions, and use thereof
WO2006121521A2 (en) 2005-05-10 2006-11-16 Angiotech International Ag Soft tissue implants, anti-scarring agents, and therapeutic compositions
WO2006121522A2 (en) 2005-05-10 2006-11-16 Angiotech International Ag Implantable sensors and pumps, anti-scarring agents, and therapeutic compositions
EP1948195A2 (en) 2005-11-17 2008-07-30 Innate Pharma Improved methods of using phosphoantigen for the treatment of cancer
US20090247734A1 (en) 2005-12-14 2009-10-01 Hendrickson Wayne A Chemically Derivatized CD4 and Uses Thereof
CA2639070A1 (en) 2006-04-13 2007-11-01 Oncomethylime Sciences S.A. Novel tumour suppressor
WO2008012692A2 (en) 2006-05-26 2008-01-31 Methylgene Inc. Assay for efficacy of histone deacetylase inhibitors
KR101504669B1 (ko) 2006-10-19 2015-03-20 시그날 파마소티칼 엘엘씨 헤테로아릴 화합물, 이들의 조성물 그리고 단백질 키나아제 억제제로서의 이들의 용도
CN101657217B (zh) 2007-01-30 2013-11-20 药品循环公司 确定癌症对组蛋白脱乙酰酶抑制剂的抗性的方法
CA2693707A1 (en) 2007-07-13 2009-03-05 The Johns Hopkins University B7-dc variants
WO2009023193A1 (en) 2007-08-15 2009-02-19 Cytokinetics, Incorporated Certain chemical entities, compositions, and methods
KR20100072024A (ko) 2007-09-14 2010-06-29 메틸진 인크. 히스톤 탈아세틸화 효소 ｈｄａｃ1, ｈｄａｃ2 및/또는 ｈｄａｃ3의 선택적 억제제 및 미세관 안정화제로의 암 병용 치료법
GB0802009D0 (en) 2008-02-04 2008-03-12 Chroma Therapeutics Ltd Biomarkers of aminopeptidase inhibition
JP2009209090A (ja) 2008-03-04 2009-09-17 Mitsui Chemicals Inc 殺虫剤及び該殺虫剤に含まれる化合物、並びに該化合物の使用方法
WO2009147781A1 (ja) 2008-06-02 2009-12-10 国立大学法人東京大学 抗がん剤
CN102203125A (zh) 2008-08-25 2011-09-28 安普利穆尼股份有限公司 Pd-1拮抗剂及其使用方法
TWI453207B (zh) 2008-09-08 2014-09-21 Signal Pharm Llc 胺基三唑并吡啶，其組合物及使用其之治療方法
US20160041153A1 (en) 2008-11-12 2016-02-11 Kirk Brown Biomarker compositions and markers
CN101756957B (zh) 2008-12-26 2012-11-14 鼎泓国际投资（香港）有限公司 含有青蒿素及青蒿素类衍生物和组蛋白去乙酰化酶抑制剂的药物组合物及其应用
CN101757626B (zh) 2008-12-26 2012-12-12 鼎泓国际投资（香港）有限公司 含有胰岛素样生长因子-i受体抑制剂和组蛋白去乙酰化酶抑制剂的药物组合物及其应用
CN101836989B (zh) 2009-03-19 2013-02-13 鼎泓国际投资（香港）有限公司 含有粉防己碱及粉防己碱类衍生物和组蛋白去乙酰化酶抑制剂的药物组合物及其应用
CN101837129B (zh) 2009-03-19 2012-12-12 鼎泓国际投资（香港）有限公司 含cMet抑制剂、HDAC抑制剂与EGFR酪氨酸激酶抑制剂的药物组合物及其应用
EP2494077A4 (en) 2009-10-27 2013-08-21 Caris Mpi Inc MOLECULAR PROFILING FOR PERSONALIZED MEDICINE
CN102711479A (zh) 2009-11-06 2012-10-03 无限药品股份有限公司 Hedgehog通道抑制剂的口服制剂
JP2013510585A (ja) 2009-11-13 2013-03-28 インフィニティー ファーマシューティカルズ， インコーポレイテッド 癌の同定、評価、予防および治療のための組成物、キットおよび方法
WO2011063309A1 (en) 2009-11-20 2011-05-26 Infinity Pharmaceuticals, Inc. Methods and compositions for treating hedgehog-associated cancers
SG10201501062SA (en) 2010-02-11 2015-04-29 Celgene Corp Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same
BR112012024565B1 (pt) 2010-03-26 2022-02-08 Trustees Of Dartmouth College Proteína de fusão vista imunossupressora multimérica isolada ou recombinante e composição
WO2011127219A1 (en) 2010-04-06 2011-10-13 Caris Life Sciences Luxembourg Holdings Circulating biomarkers for disease
JO2998B1 (ar) 2010-06-04 2016-09-05 Amgen Inc مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان
WO2011155898A1 (en) 2010-06-11 2011-12-15 Wadell Goeran New antiviral compounds
US20120010229A1 (en) 2010-07-08 2012-01-12 Macdougall John R Therapeutic regimens for hedgehog-associated cancers
WO2012006589A2 (en) 2010-07-08 2012-01-12 Infinity Pharmaceuticals, Inc. Methods and compositions for identification, assessment and treatment of cancers associated with hedgehog signaling
CA2808417A1 (en) 2010-08-18 2012-02-23 Caris Life Sciences Luxembourg Holdings, S.A.R.L. Circulating biomarkers for disease
CN102441167B (zh) 2010-10-12 2014-05-07 鼎泓国际投资（香港）有限公司 含有芹菜素及芹菜素类衍生物和组蛋白去乙酰化酶抑制剂的药物组合物及其应用
US9808434B2 (en) 2011-01-27 2017-11-07 City Of Hope Compound for treating cancer and diabetes
AU2012220872A1 (en) 2011-02-22 2013-09-12 Caris Life Sciences Switzerland Holdings Gmbh Circulating biomarkers
WO2012167086A2 (en) 2011-06-03 2012-12-06 President And Fellows Of Harvard College Methods of diagnosing and treating amyotrophic lateral sclerosis
WO2012170711A1 (en) 2011-06-07 2012-12-13 Caris Life Sciences Luxembourg Holdings, S.A.R.L Circulating biomarkers for cancer
BR112013032232A2 (pt) 2011-06-16 2016-09-20 Caris Life Sciences Switzerland Holdings S A R L método de caracterização de câncer através do uso de biomarcador de ácido nucleico
WO2013028907A1 (en) 2011-08-23 2013-02-28 Infinity Pharmaceuticals, Inc. Biomarkers predictive of therapeutic responsiveness to hsp90 inhibitors and uses thereof
WO2013039956A2 (en) 2011-09-14 2013-03-21 The Trustees Of Columbia University In The City Of New York Compositions and methods for treating mood disorders
PE20142361A1 (es) 2011-09-30 2015-01-16 Dana Farber Cancer Inst Inc Peptidos terapeuticos
ES2784194T3 (es) 2011-11-30 2020-09-23 Ludwig Inst For Cancer Res Ltd Moduladores de células iNKT y métodos para uso el mismo
WO2013085902A1 (en) 2011-12-05 2013-06-13 The University Of Texas M.D. Combination therapy methods for treating an inflammatory breast cancer
JP2015512616A (ja) 2012-02-01 2015-04-30 コンピュゲン エルティーディー． Ｃ１ｏｒｆ３２抗体およびがんの治療のためのその使用
WO2013124867A1 (en) 2012-02-21 2013-08-29 Amrita Vishwa Vidyapeetham University Polymer - polymer or polymer - protein core - shell nano medicine loaded with multiple drug molecules
EP2823306A4 (en) 2012-03-09 2015-11-11 Caris Life Sciences Switzerland Holdings Gmbh BIOMARKER COMPOSITIONS AND METHODS
KR20150018870A (ko) 2012-06-06 2015-02-24 바이오노르 이뮤노 에이에스 면역원 및 투여 반응제로서 사용하기 위한 바이러스 단백질로부터 유래하는 펩타이드
JP2015520179A (ja) 2012-06-06 2015-07-16 ビオノール イミュノ エーエスＢｉｏｎｏｒ Ｉｍｍｕｎｏ Ａｓ ワクチン
AU2013278843A1 (en) 2012-06-21 2014-03-27 Compugen Ltd. LSR antibodies, and uses thereof for treatment of cancer
US10314807B2 (en) 2012-07-13 2019-06-11 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
US10258596B2 (en) 2012-07-13 2019-04-16 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
HUE046292T2 (hu) 2012-08-13 2020-02-28 Univ Rockefeller Melanóma kezelése és diagnosztizálása
US9382329B2 (en) 2012-08-14 2016-07-05 Ibc Pharmaceuticals, Inc. Disease therapy by inducing immune response to Trop-2 expressing cells
AU2013302696B9 (en) 2012-08-14 2018-08-09 Ibc Pharmaceuticals, Inc. T-cell redirecting bispecific antibodies for treatment of disease
US9682143B2 (en) 2012-08-14 2017-06-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
MX375442B (es) 2012-09-21 2025-03-06 Intensity Therapeutics Inc Un agente terapéutico y un agente mejorador de la permeación intracelular para usarse en el tratamiento de cáncer.
EP2914722A1 (en) 2012-11-05 2015-09-09 Pronai Therapeutics, Inc. Dosing and administration of oligonucleotide cancer therapies
CA2890288A1 (en) 2012-11-16 2014-05-22 Merck Patent Gmbh Novel heterocyclic derivatives as modulators of kinase activity
US20150301058A1 (en) 2012-11-26 2015-10-22 Caris Science, Inc. Biomarker compositions and methods
CN103833626B (zh) 2012-11-27 2015-11-25 深圳微芯生物科技有限责任公司 西达本胺的晶型及其制备方法与应用
CA2887539C (en) 2012-11-29 2021-10-26 Merck Patent Gmbh Azaquinazoline carboxamide derivatives
BR112015013444B1 (pt) 2012-12-13 2022-11-01 Immunomedics, Inc Uso de um imunoconjugado
ES2819573T3 (es) 2012-12-13 2021-04-16 Immunomedics Inc Método para producir inmunoconjugados de anticuerpo-SN-38 con un enlazador CL2A
US9492566B2 (en) 2012-12-13 2016-11-15 Immunomedics, Inc. Antibody-drug conjugates and uses thereof
US10137196B2 (en) 2012-12-13 2018-11-27 Immunomedics, Inc. Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
EP2954755B1 (en) 2013-02-07 2018-09-12 Philips Lighting Holding B.V. A lighting system having a controller that contributes to a selected light scene, and a method for controlling such a system
CN105209068A (zh) 2013-02-07 2015-12-30 免疫医疗公司 用于靶向癌症治疗的缀合至抗体的高效2-吡咯啉多柔比星的前药形式(p2pdox)
CN104056270B (zh) 2013-02-21 2018-11-09 中国人民解放军军事医学科学院野战输血研究所 用于制备多器官损伤救治药物的组蛋白去乙酰化酶抑制剂
AU2014224975B2 (en) 2013-03-05 2017-09-14 Merck Patent Gmbh Triazolo(4,5-d)pyrimidine derivatives for the treatment of diseases such as cancer
US9617266B2 (en) 2013-03-05 2017-04-11 Merck Patent Gmbh Imidazopyrimidine derivatives
EP2970130A4 (en) 2013-03-14 2016-08-03 Seragon Pharmaceuticals Inc MODULATORS OF POLYCYCLIC STROGEN RECEPTORS AND USES THEREOF
LT2970473T (lt) 2013-03-14 2017-10-25 Bristol-Myers Squibb Company Dr5 agonisto ir anti-pd-1 antagonisto derinys ir naudojimo būdai
EP2970965A2 (en) 2013-03-15 2016-01-20 Pronai Therapeutics, Inc. Dnai for the modulation of genes
US9308236B2 (en) 2013-03-15 2016-04-12 Bristol-Myers Squibb Company Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
AR095363A1 (es) * 2013-03-15 2015-10-14 Genentech Inc Biomarcadores y métodos para el tratamiento de condiciones relacionadas con pd-1 y pd-l1
EP3666886A1 (en) 2013-03-15 2020-06-17 Dana-Farber Cancer Institute, Inc. Therapeutic peptides
CN104069106A (zh) 2013-03-27 2014-10-01 南通瑞思医药技术有限公司 苯甲酰胺类化合物在制备激活潜伏艾滋病病毒药物中的应用
CN105209047B (zh) 2013-04-18 2020-08-18 免疫设计股份有限公司 用于癌症治疗的gla单一疗法
WO2014189648A1 (en) 2013-05-24 2014-11-27 Cooper Human Systems Llc Methods and compositions for treatment of hiv infection
WO2014193999A2 (en) 2013-05-28 2014-12-04 Caris Science, Inc. Biomarker methods and compositions
KR20160021277A (ko) 2013-06-19 2016-02-24 세라곤 파마슈티컬스, 인크. 에스트로겐 수용체 조절제 및 이의 용도
CA2915534A1 (en) 2013-06-19 2014-12-24 Seragon Pharmaceuticals, Inc. Azetidine estrogen receptor modulators and uses thereof
CN105492439B (zh) 2013-06-21 2019-11-22 齐尼思表观遗传学有限公司 作为溴结构域抑制剂的取代的双环化合物
WO2015007337A1 (en) 2013-07-19 2015-01-22 Bionor Immuno As Method for the vaccination against hiv
AU2014293013A1 (en) 2013-07-26 2016-03-17 Race Oncology Ltd. Combinatorial methods to improve the therapeutic benefit of bisantrene
AU2014298959B2 (en) 2013-07-29 2018-04-05 Merck Patent Gmbh 1,3-disubstituted cyclopentane derivatives
WO2015017546A1 (en) 2013-07-30 2015-02-05 H. Lee Moffitt Cancer Center And Research Institute, Inc. Selective histone deactylase 6 inhibitors
WO2015015318A2 (en) 2013-07-31 2015-02-05 Zenith Epigenetics Corp. Novel quinazolinones as bromodomain inhibitors
PT3027598T (pt) 2013-07-31 2017-07-17 Merck Patent Gmbh Derivados de oxoquinazolinil-butanamida
CA2920377A1 (en) 2013-08-05 2015-02-12 Cambridge Enterprise Limited Inhibition of cxcr4 signaling in cancer immunotherapy
KR102249564B1 (ko) 2013-08-07 2021-05-07 메르크 파텐트 게엠베하 피페리딘 우레아 유도체
US20160201063A1 (en) 2013-08-16 2016-07-14 Rana Therapeutics, Inc. Epigenetic regulators of frataxin
CN103432077A (zh) 2013-08-21 2013-12-11 北京淦航医药科技有限公司 西达苯胺固体分散制剂
WO2015035112A1 (en) 2013-09-05 2015-03-12 The Johns Hopkins University Cancer therapy via a combination of epigenetic modulation and immune modulation
WO2015037000A1 (en) 2013-09-11 2015-03-19 Compugen Ltd Vstm5 polypeptides and uses thereof as a drug for treatment of cancer, infectious diseases and immune related diseases
US20160272707A1 (en) 2013-09-11 2016-09-22 Compugen Ltd. Vstm5 antibodies, and uses thereof for treatment of cancer, infectious diseases and immune related diseases
WO2015048547A2 (en) 2013-09-26 2015-04-02 Rigel Pharmaceuticals, Inc. Methods for using and biomarkers for ampk-activating compounds
US20150094518A1 (en) 2013-09-27 2015-04-02 The Regents Of The University Of California Modular polymer platform for the treatment of cancer
EP3060654B1 (en) 2013-10-21 2023-03-15 Hemoshear, LLC In vitro model for a tumor microenvironment
SG10201901902WA (en) 2013-10-21 2019-04-29 Merck Patent Gmbh Heteroaryl compounds as btk inhibitors and uses thereof
US20170080093A1 (en) 2013-10-22 2017-03-23 Tyme, Inc. Tyrosine Derivatives And Compositions Comprising Them
EP3060563B1 (en) 2013-10-25 2018-05-02 Novartis AG Ring-fused bicyclic pyridyl derivatives as fgfr4 inhibitors
CA2929715A1 (en) 2013-11-07 2015-05-14 Deciphera Pharmaceuticals, Llc Methods for inhibiting tie2 kinase useful in the treatment of cancer
US9457019B2 (en) 2013-11-07 2016-10-04 Deciphera Pharmaceuticals, Llc Methods for inhibiting tie-2 kinase useful in the treatment of cancer
US10758636B2 (en) 2013-11-12 2020-09-01 Centre For Probe Development And Commercialization Residualizing linkers and uses thereof
CA2929181A1 (en) 2013-11-13 2015-05-21 Novartis Ag Mtor inhibitors for enhancing the immune response
RU2720237C2 (ru) 2013-11-18 2020-04-28 Форма Терапеутикс, Инк. Композиции, содержащие бензопиперазин, в качестве ингибиторов бромодоменов вет
CN105934246B (zh) 2013-11-18 2019-10-22 福马疗法公司 作为bet溴域抑制剂的四氢喹啉组成物
WO2015077717A1 (en) 2013-11-25 2015-05-28 The Broad Institute Inc. Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status
CA2932767A1 (en) 2013-12-06 2015-06-11 Dana-Farber Cancer Institute, Inc. Therapeutic peptides
WO2015086738A2 (en) 2013-12-11 2015-06-18 Bionor Immuno As Hiv vaccine
WO2015089380A2 (en) 2013-12-12 2015-06-18 Celcuity Llc Assays and methods for determining the responsiveness of an individual subject to a therapeutic agent
US20160263092A1 (en) 2013-12-19 2016-09-15 Twi Biotechnology, Inc. Therapeutic uses of berberine formulations
ES2883289T3 (es) 2013-12-20 2021-12-07 Astex Therapeutics Ltd Compuestos heterocíclicos bicíclicos y sus usos en terapia
EP3082853A2 (en) 2013-12-20 2016-10-26 The Broad Institute, Inc. Combination therapy with neoantigen vaccine
PE20160996A1 (es) 2013-12-23 2016-11-09 Bayer Pharma AG Conjugados de farmacos anticuerpo (adcs) con inhibidores de ksp
LT3087076T (lt) 2013-12-23 2017-12-27 Merck Patent Gmbh Imidazopirazinono dariniai
AU2015204572B2 (en) 2014-01-10 2020-07-30 Inspirna, Inc. LXR agonists and uses thereof
CN104771363A (zh) 2014-01-14 2015-07-15 深圳微芯生物科技有限责任公司 一种西达本胺固体分散体及其制备方法与应用
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
WO2015110659A1 (en) 2014-01-27 2015-07-30 Bionor Immuno As Methods of immunization with a vaccine inducing a humoral immune response and with a vaccine inducing a cellular immune response
US10449245B2 (en) 2014-01-27 2019-10-22 Bionor Immuno As Method for reducing HIV-1 reservoir size using multivalent immunogen and reservoir purging agent
AU2015208033B2 (en) 2014-01-27 2019-02-07 Bionor Immuno As Method for the vaccination against HIV
US9631013B2 (en) 2014-01-28 2017-04-25 Fibrogen, Inc. Therapeutic method for pancreatic cancer
WO2015113927A1 (en) 2014-01-29 2015-08-06 Bayer Pharma Aktiengesellschaft Amino-substituted isothiazoles
EP3099682A1 (en) 2014-01-29 2016-12-07 Bayer Pharma Aktiengesellschaft Amino-substituted isothiazoles
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
US10619210B2 (en) 2014-02-07 2020-04-14 The Johns Hopkins University Predicting response to epigenetic drug therapy
AU2015223049B2 (en) 2014-02-27 2019-03-21 Merck Patent Gmbh Heterocyclic compounds as NaV channel inhibitors and uses thereof
JP2017513812A (ja) 2014-02-28 2017-06-01 ザ ロイヤル インスティチューション フォー ジ アドヴァンスメント オブ ラーニング／マギル ユニヴァーシティ 免疫療法用のａｐｃ活性剤としてのｔｃ−ｐｔｐ阻害剤
BR112016020897A2 (pt) 2014-03-11 2018-01-23 Council Queensland Inst Medical Res ?determinação da agressividade de câncer, prognóstico e capacidade de reação a tratamento?
CA2940576A1 (en) 2014-03-13 2015-09-17 F. Hoffmann-La Roche Ag Therapeutic combinations with estrogen receptor modulators
AU2015228860A1 (en) 2014-03-13 2016-09-08 F. Hoffmann-La Roche Ag Methods and compositions for modulating estrogen receptor mutants
LT3116909T (lt) 2014-03-14 2020-02-10 Novartis Ag Antikūno molekulės prieš lag-3 ir jų panaudojimas
CN113616656B (zh) 2014-03-19 2023-02-17 无限药品股份有限公司 用于治疗PI3K-γ介导的障碍的杂环化合物
CN104974079A (zh) 2014-04-02 2015-10-14 C&C生物医药有限公司 苯胺相关化合物的酰胺衍生物及其组合物
UY36060A (es) 2014-04-02 2015-10-30 Bayer Pharma AG Compuestos de azol sustituidos con amida
EP3129472A4 (en) 2014-04-03 2017-11-01 University of Maryland, Baltimore Microtentacle imaging in patient tumor samples
CN106916100B (zh) 2014-04-04 2020-09-15 深圳微芯生物科技股份有限公司 一种e构型苯甲酰胺类化合物及其药用制剂
US9987258B2 (en) 2014-04-06 2018-06-05 H. Lee Moffitt Cancer Center And Research Institute, Inc. Histone deacetylase as a modulator of PDL1 expression and activity
WO2015157093A1 (en) 2014-04-08 2015-10-15 Rigel Pharmaceuticals, Inc. 2,3-disubstituted pyridine compounds as tgf-beta inhibitors and methods of use
NO2776305T3 (OSRAM) 2014-04-23 2018-01-27
JP2015209376A (ja) 2014-04-24 2015-11-24 国立大学法人北海道大学 腫瘍特異的免疫増強剤
US10308597B2 (en) 2014-04-30 2019-06-04 Rgenix, Inc. Inhibitors of creatine transport and uses thereof
WO2015168614A2 (en) 2014-05-01 2015-11-05 Board Of Regents Of The University Of Nebraska Polymer compositions of histone deacetylase inhibitors and methods of use thereof
WO2015172747A1 (en) 2014-05-16 2015-11-19 Zhaoyin Wang Spirocyclic molecules as mth1 inhibitors
GB201409471D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
WO2015184405A1 (en) 2014-05-30 2015-12-03 Medivation Technologies, Inc. Aromatic compounds, compositions and uses thereof
US11034757B2 (en) 2014-06-09 2021-06-15 Biomed Valley Discoveries, Inc. Combination therapies using agents that target tumor-associated stroma or tumor cells and tumor vasculature
TWI681954B (zh) 2014-06-12 2020-01-11 美商西爾拉癌症醫學公司 Ｎ-（氰基甲基）-４-（２-（４-𠰌啉基苯基胺基）嘧啶-４-基）苯甲醯胺
EA201692265A1 (ru) 2014-06-13 2017-05-31 Джилид Сайэнс, Инк. Ингибиторы фосфатидилинозитол-3-киназы
ES2763103T3 (es) 2014-06-13 2020-05-27 Gilead Sciences Inc Inhibidor de la fosfatidilinositol 3-quinasa
NZ726360A (en) 2014-06-13 2018-04-27 Gilead Sciences Inc Phosphatidylinositol 3-kinase inhibitors
EA201692266A1 (ru) 2014-06-13 2017-06-30 Джилид Сайэнс, Инк. Ингибиторы фосфатидилинозитол-3-киназы
CN106458932A (zh) 2014-06-13 2017-02-22 吉利德科学公司 磷脂酰肌醇3‑激酶抑制剂
JP6527534B2 (ja) 2014-06-16 2019-06-05 ファンダシオン パラ ラ インベスティガシオン メディカ アプリカダＦｕｎｄａｃｉｏｎ Ｐａｒａ Ｌａ Ｉｎｖｅｓｔｉｇａｓｉｏｎ Ｍｅｄｉｃａ Ａｐｌｉｃａｄａ ヒストンメチルトランスフェラーゼ及びｄｎａメチルトランスフェラーゼの二重阻害剤としての新規化合物
UY36175A (es) 2014-06-17 2016-01-29 Bayer Pharma AG 3-amino-1,5,6,7-tetrahidro-4h-indol-4-onas
NO2717902T3 (OSRAM) 2014-06-20 2018-06-23
TW201613936A (en) 2014-06-20 2016-04-16 Gilead Sciences Inc Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
AR100975A1 (es) 2014-06-24 2016-11-16 Gilead Sciences Inc Inhibidores de fosfatidilinositol 3-quinasa
WO2015200790A2 (en) 2014-06-26 2015-12-30 Yale University Compositions and methods to regulate renalase in the treatment of diseases and disorders
WO2016005508A1 (en) * 2014-07-11 2016-01-14 Bionor Immuno As Method for reducing and/or delaying pathological effects of human immunodeficiency virus i (hiv) or for reducing the risk of developing acquired immunodeficiency syndrome (aids)
KR20190104438A (ko) 2014-07-11 2019-09-09 길리애드 사이언시즈, 인코포레이티드 Hiv의 치료를 위한 톨-유사 수용체의 조정제
JP6626085B2 (ja) 2014-07-15 2019-12-25 ザ・ジョンズ・ホプキンス・ユニバーシティー 骨髄由来抑制細胞の抑制及び免疫チェックポイント阻害の方法
CN104083763A (zh) 2014-07-16 2014-10-08 中国人民解放军军事医学科学院野战输血研究所 组蛋白去乙酰化酶抑制剂在制备潜伏病毒激活剂中的应用
EP3169678A1 (en) 2014-07-17 2017-05-24 Merck Patent GmbH Novel naphthryidines and isoquinolines and their use as cdk8/19 inhibitors
WO2016014890A1 (en) 2014-07-24 2016-01-28 Calithera Biosciences, Inc. Treatment of multiple myeloma with heterocyclic inhibitors of glutaminase
EP3172204A1 (en) 2014-07-25 2017-05-31 Bayer Pharma Aktiengesellschaft Amino-substituted isoxazoles
EP3174974B1 (en) 2014-07-29 2020-05-20 Novartis AG Il-15 and il-15ralpha heterodimer dose escalation regimens for treating conditions
TWI700283B (zh) 2014-08-04 2020-08-01 德商拜耳製藥公司 ２-(嗎啉-４-基)-１,７-萘啶
EP4180041A1 (en) 2014-08-07 2023-05-17 Mayo Foundation for Medical Education and Research Compounds and methods for treating cancer
GB201414464D0 (en) 2014-08-14 2014-10-01 Technion Res & Dev Foundation Compositions and methods for therapeutics prescreening
AU2015304438B2 (en) 2014-08-18 2019-06-20 Ono Pharmaceutical Co., Ltd. Acid-addition salt of Trk-inhibiting compound
JO3663B1 (ar) 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
US10912933B2 (en) 2014-08-19 2021-02-09 The Regents Of The University Of California Implants for localized drug delivery and methods of use thereof
JP2017525721A (ja) 2014-08-26 2017-09-07 ファンダシオン パラ ラ インベスティガシオン メディカ アプリカダＦｕｎｄａｃｉｏｎ Ｐａｒａ Ｌａ Ｉｎｖｅｓｔｉｇａｓｉｏｎ Ｍｅｄｉｃａ Ａｐｌｉｃａｄａ 認知欠損または認知障害に伴って進行する神経障害のおよび神経変性疾患の処置および予防のための製品
EP3186239B1 (en) 2014-08-29 2018-10-10 Gilead Sciences, Inc. Antiretroviral agents
US20160067255A1 (en) 2014-09-04 2016-03-10 Gilead Sciences, Inc. Methods of treating or preventing hiv in patients using a combination of tenofovir alafenamide and dolutegravir
BR112017004826A2 (pt) 2014-09-13 2017-12-12 Novartis Ag terapias de combinação de inibidores de alk
CN106715431A (zh) 2014-09-16 2017-05-24 吉利德科学公司 Toll样受体调节剂的固体形式
EP3194380A1 (en) 2014-09-19 2017-07-26 Bayer Pharma Aktiengesellschaft Benzyl substituted indazoles as bub1 kinase inhibitors
WO2016042081A1 (en) 2014-09-19 2016-03-24 Bayer Pharma Aktiengesellschaft Benzyl substituted indazoles as bub1 kinase inhibitors
CR20170100A (es) 2014-09-19 2017-04-24 Bayer Pharma Aktiengesellchaft Indazoles sustituidos con bencilo como inhibidores bub1
CN107148420A (zh) 2014-09-19 2017-09-08 拜耳制药股份公司 苄基取代的吲唑类化合物
AU2015317566B2 (en) 2014-09-19 2019-10-10 Mackay Medical Foundation The Presbyterian Church In Taiwan Mackay Memorial Hospital Benzo-heterocyclic compounds and their applications
EP3198276B1 (en) 2014-09-24 2023-09-20 Exscientia GmbH Monolayer of pbmcs or bone-marrow cells and uses thereof
CN104530413B (zh) 2014-10-01 2017-08-25 厦门赛诺邦格生物科技股份有限公司 一种多官能化h型聚乙二醇衍生物修饰的生物相关物质
CN104725628B (zh) 2014-10-01 2018-04-17 厦门赛诺邦格生物科技股份有限公司 一种含可降解基团的单一官能化支化聚乙二醇、制备方法及其生物相关物质
CN104530415B (zh) 2014-10-01 2017-09-01 厦门赛诺邦格生物科技股份有限公司 一种异官能化y型聚乙二醇衍生物、制备方法及其生物相关物质
AU2015327868A1 (en) 2014-10-03 2017-04-20 Novartis Ag Combination therapies
KR102523111B1 (ko) 2014-10-06 2023-04-18 메르크 파텐트 게엠베하 Btk 억제제로서 헤테로아릴 화합물 및 이들의 용도
US9446148B2 (en) 2014-10-06 2016-09-20 Mayo Foundation For Medical Education And Research Carrier-antibody compositions and methods of making and using the same
US9732119B2 (en) 2014-10-10 2017-08-15 Bristol-Myers Squibb Company Immunomodulators
KR20230004907A (ko) 2014-10-14 2023-01-06 립타이드 바이오사이언스, 인코포레이티드 항-염증 특성을 갖는 펩타이드
EP3206711B1 (en) 2014-10-14 2023-05-31 Novartis AG Antibody molecules to pd-l1 and uses thereof
WO2016061495A1 (en) 2014-10-16 2016-04-21 Predictive Therapeutics Ltd. Atavarsitic systems and methods for biomarker discovery
WO2016065349A2 (en) 2014-10-24 2016-04-28 University Of Maryland, Baltimore Short non-coding protein regulatory rnas (sprrnas) and methods of use
EP3212228B1 (en) 2014-10-27 2025-12-03 Ruprecht-Karls-Universität Heidelberg Maraviroc alone or in combination therapy for the treatment of cancer
PT3643709T (pt) 2014-10-30 2021-12-20 Kangpu Biopharmaceuticals Ltd Derivado, intermediário, método de preparação, composição farmacêutica de isoindolina e utilização dos mesmos
AU2015338974B2 (en) * 2014-10-31 2021-08-26 Oncomed Pharmaceuticals, Inc. Combination therapy for treatment of disease
WO2016070089A2 (en) 2014-10-31 2016-05-06 Abbvie Biotherapeutics Inc. Anti-cs1 antibodies and antibody drug conjugates
JP7305300B2 (ja) * 2014-11-05 2023-07-10 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 併用免疫療法
US20180298447A1 (en) 2014-11-07 2018-10-18 Rheinisch Friedrich-Wilhelms-Universität Bonn Institut Für Rekonstruktive Neurobiologie Methods for assessing the treatment response of cancer patients and for treating cancer patients by analysing cpg methylation
US9856292B2 (en) 2014-11-14 2018-01-02 Bristol-Myers Squibb Company Immunomodulators
EA201791050A1 (ru) 2014-11-14 2017-09-29 Новартис Аг Конъюгаты антител и лекарственных средств
EP3750545B1 (en) 2014-11-17 2024-03-27 Cellectar Biosciences, Inc. Phospholipid ether analogs as cancer-targeting drug vehicles
KR20170096112A (ko) 2014-11-17 2017-08-23 제넨테크, 인크. Ox40 결합 효능제 및 pd-1 축 결합 길항제를 포함하는 조합 요법
WO2016081732A1 (en) 2014-11-19 2016-05-26 Memorial Sloan-Kettering Cancer Center Thienopyrimidines and uses thereof
SG11201702741SA (en) 2014-11-20 2017-04-27 Merck Patent Gmbh Heteroaryl compounds as irak inhibitors and uses thereof
EP3227281A4 (en) 2014-12-01 2018-05-30 Zenith Epigenetics Ltd. Substituted pyridinones as bromodomain inhibitors
HK1246273B (en) 2014-12-01 2019-12-06 恒翼生物医药(上海)股份有限公司 Substituted pyridines as bromodomain inhibitors
US20180148789A1 (en) 2014-12-01 2018-05-31 University Of Southern California Methods for treating and assessing tumor invasion and metastasis
WO2016087488A1 (en) 2014-12-03 2016-06-09 Bayer Pharma Aktiengesellschaft Administration regime for aminoalcohol substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives
WO2016087490A1 (en) 2014-12-03 2016-06-09 Bayer Pharma Aktiengesellschaft Combination of pi3k-inhibitors
EP3227340B1 (en) 2014-12-04 2020-06-17 Mediterranea Theranostic S.R.L. Humanized anti-trop-2 monoclonal antibodies and uses thereof
EP3229837B1 (en) 2014-12-08 2025-02-05 Dana-Farber Cancer Institute, Inc. Methods for upregulating immune responses using combinations of anti-rgmb and anti-pd-1 agents
DK3587417T3 (da) 2014-12-09 2022-03-28 Bayer Ag 1,3-thiazol-2-yl-substituerede benzamider
WO2016094309A1 (en) 2014-12-10 2016-06-16 Myosotis Inhibition of tnf signaling in cancer immunotherapy
KR102439094B1 (ko) 2014-12-12 2022-08-31 셀퀴티 인크. 환자를 진단 및 치료하기 위한 신호전달 경로 활성의 측정 방법
EP3233127A1 (de) 2014-12-15 2017-10-25 Bayer Pharma Aktiengesellschaft Antikörper-wirkstoff-konjugate (adcs) von ksp-inhibitoren mit aglycosylierten anti-tweakrantikörpern
US20190125745A1 (en) 2014-12-17 2019-05-02 Rgenix, Inc. Treatment and diagnosis of cancer
EP3233802A1 (en) 2014-12-18 2017-10-25 Bayer Pharma Aktiengesellschaft Substituted pyridyl-cycloalkyl-carboxylic acids, compositions containing them and medical uses thereof
ES2819448T3 (es) 2014-12-18 2021-04-16 Hoffmann La Roche Tetrahidro-pirido[3,4-b]indoles como moduladores del receptor de estrógenos y usos de los mismos
WO2016097071A1 (en) 2014-12-18 2016-06-23 F. Hoffmann-La Roche Ag Estrogen receptor modulators and uses thereof
WO2016097073A1 (en) 2014-12-18 2016-06-23 F. Hoffmann-La Roche Ag Derivatives of 2,3-diphenylchromene useful for the treatment of cancer
US9861680B2 (en) 2014-12-18 2018-01-09 Bristol-Myers Squibb Company Immunomodulators
US9944678B2 (en) 2014-12-19 2018-04-17 Bristol-Myers Squibb Company Immunomodulators
ES2724367T3 (es) 2014-12-19 2019-09-10 Epigenomics Ag Métodos para detectar la metilación de CpG y para el diagnóstico del cáncer
EP3234193B1 (en) 2014-12-19 2020-07-15 Massachusetts Institute of Technology Molecular biomarkers for cancer immunotherapy
EP3233918A1 (en) 2014-12-19 2017-10-25 Novartis AG Combination therapies
WO2016102493A1 (en) 2014-12-22 2016-06-30 Bayer Pharma Aktiengesellschaft Imidazopyridine ezh2 inhibitors
CA2971536A1 (en) 2014-12-23 2016-06-30 Bayer Pharma Aktiengesellschaft 6-hydroxybenzofuranyl- and 6-alkoxybenzofuranyl-substituted imidazopyridazines
TWI738321B (zh) 2014-12-23 2021-09-01 美商基利科學股份有限公司 多環胺甲醯基吡啶酮化合物及其醫藥用途
DE102014226903A1 (de) 2014-12-23 2016-06-23 Olympus Winter & Ibe Gmbh HF-Hilfsstoff, medizinisches System und Verfahren zum selektiven Behandeln von Krebsgewebe
US10336702B2 (en) 2014-12-23 2019-07-02 Bergenbio Asa Pharmaceutically active compounds
BR112017013491A2 (pt) 2014-12-24 2018-01-09 Gilead Sciences, Inc. compostos de pirimidina fundida para o tratamento de hiv
TWI699355B (zh) 2014-12-24 2020-07-21 美商基利科學股份有限公司 喹唑啉化合物
WO2016105534A1 (en) 2014-12-24 2016-06-30 Gilead Sciences, Inc. Isoquinoline compounds for the treatment of hiv
WO2016111947A2 (en) * 2015-01-05 2016-07-14 Jounce Therapeutics, Inc. Antibodies that inhibit tim-3:lilrb2 interactions and uses thereof
CA2972846A1 (en) 2015-01-08 2016-07-14 Hackensack University Medical Center Ex vivo methods for minimizing risks and maximizing benefits of allogeneic blood and marrow transplantation
WO2016111834A1 (en) 2015-01-09 2016-07-14 Reiley Pharmaceuticals, Inc. Cox-2-targeting, platinum-containing conjugates and their use in the treatment of tumors and cancers
AU2016209046A1 (en) 2015-01-23 2017-07-20 Aclaris Therapeutics, Inc. Heterocyclic ITK inhibitors for treating inflammation and cancer
JP6655249B2 (ja) 2015-01-23 2020-02-26 国立大学法人 鹿児島大学 Ｈｉｖ−１感染細胞殺傷剤及びその用途
TN2017000329A1 (en) 2015-01-28 2019-01-16 Bayer Pharma AG 4h-pyrrolo[3,2-c]pyridin-4-one derivatives
CN107427516B8 (zh) 2015-01-30 2021-04-09 昂克希尔迪克斯有限公司 7-苄基-4-(2-甲基苄基)-2,4,6,7,8,9-六氢咪唑并[1,2-a]吡啶并[3,4-e]嘧啶-5(1h)-酮、其类似物、及其盐、以及它们用于治疗的方法
TW201639573A (zh) 2015-02-03 2016-11-16 吉李德科學股份有限公司 有關治療癌症之合併治療
US20160222060A1 (en) 2015-02-04 2016-08-04 Bristol-Myers Squibb Company Immunomodulators
KR20170109546A (ko) 2015-02-05 2017-09-29 메르크 파텐트 게엠베하 Irak1/4 억제제로서의 매크로시클릭 화합물 및 이들의 용도
CN107428765B (zh) 2015-02-06 2020-12-29 默克专利有限公司 用作irak抑制剂的哒嗪酮类大环化合物及其用途
US20180028531A1 (en) 2015-02-12 2018-02-01 BeyondSpring Phamaceuticals, Inc. Use of plinabulin in combination with immune checkpoint inhibitors
EP3258941A4 (en) 2015-02-17 2018-09-26 Cantex Pharmaceuticals, Inc. Treatment of cancers and hematopoietic stem cell disorders privileged by cxcl12-cxcr4 interaction
CA2976752C (en) 2015-02-20 2019-12-17 Daiichi Sankyo Company, Limited Method for treating cancer by combined use
TN2017000374A1 (en) 2015-03-02 2019-01-16 Bristol Myers Squibb Co TGF-β INHIBITORS
PL3321265T3 (pl) 2015-03-04 2020-11-16 Gilead Sciences, Inc. Związki 4,6-diamino-pirydo[3,2-d]pirymidynowe i ich wykorzystanie jako modulatorów receptorów toll-podobnych
WO2016142313A1 (en) 2015-03-09 2016-09-15 Bayer Pharma Aktiengesellschaft Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines
EP3268490B1 (en) 2015-03-09 2020-07-08 Bayer Pharma Aktiengesellschaft Substituted 2,3-dihydroimidazo[1,2-c]quinazoline-containing combinations
US20180271891A1 (en) 2015-03-11 2018-09-27 The Broad Institute Inc. Selective treatment of prmt5 dependent cancer
EP3268013B1 (en) 2015-03-13 2021-10-13 Fondazione Telethon Il-10-producing cd4+ t cells for use in treating a cancer
US10946050B2 (en) 2015-03-16 2021-03-16 Imagilin Technology Llc Compositions comprising probiotics and methods of use thereof
US10195237B2 (en) 2015-03-16 2019-02-05 Imagilin Technology Llc Compositions and methods for treating inflammatory related diseases or conditions using Pediococcus acidilactici probiotics
WO2016149366A1 (en) 2015-03-16 2016-09-22 The Johns Hopkins University Methods and compositions for treating cancer
US9809625B2 (en) 2015-03-18 2017-11-07 Bristol-Myers Squibb Company Immunomodulators
WO2016153839A1 (en) 2015-03-20 2016-09-29 Merck Sharp & Dohme Corp. Combination of a pd-1 antagonist and vorinostat for treating cancer
WO2016153948A1 (en) 2015-03-20 2016-09-29 Deuterx, Llc Combination therapy using enantiopure, oxy-substituted, deuterium-enriched 5-(benzyl)-5-deutero-thiazolidine-2, 4-diones for treatment of medical disorders
CN107614011A (zh) 2015-03-20 2018-01-19 欣达克斯制药公司 Hdac抑制剂和抗pd‑1抗体联合用于癌症的治疗
WO2016154082A2 (en) 2015-03-23 2016-09-29 Tang Yao Methods of primary tissue culture and drug screening using autologous serum and fluids
EP3273944B1 (en) 2015-03-25 2024-11-20 The Regents of The University of Michigan Compositions and methods for delivery of biomacromolecule agents
US10302629B2 (en) 2015-03-30 2019-05-28 University Of Maryland, Baltimore Compositions and methods for treating cancer by rational targeting of protein translation
CN110790773A (zh) 2015-04-02 2020-02-14 吉利德科学公司 多环氨甲酰基吡啶酮化合物及其药物用途
SG11201707089WA (en) 2015-04-13 2017-10-30 Pfizer Chimeric antigen receptors targeting b-cell maturation antigen
WO2016166600A1 (en) 2015-04-15 2016-10-20 Trojantec Technologies Ltd Delivery of microrna using mesenchymal stem cell microparticles
EP3283463B1 (en) 2015-04-17 2021-01-20 The Trustees Of The University Of Pennsylvania Dimeric quinacrine derivatives as autophagy inhibitors for cancer therapy
MX393599B (es) 2015-04-29 2025-03-19 Radius Pharmaceuticals Inc Rad1901 para usarse en el tratamiento de cancer en sujetos con cancer positivo a receptor de estrogeno alfa resistente a farmaco
EP3288558B1 (en) 2015-04-30 2022-05-11 Bayer Pharma Aktiengesellschaft Combinations of inhibitors of irak4 with inhibitors of btk
CA2984991A1 (en) 2015-05-04 2016-11-10 Bionor Immuno As Dosage regimen for hiv vaccine
PE20181024A1 (es) 2015-05-05 2018-06-27 Bayer Pharma AG Derivados de ciclohexano sustituido con amido
WO2016183071A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Hetero-tricyclic compounds and their use for the treatment of cancer
US10314854B2 (en) 2015-05-15 2019-06-11 University Of Iowa Foundation Methods for treating tumors in situ including intratumor injection of cytotoxic particles and immune checkpoint blockade therapy
US20160339030A1 (en) 2015-05-19 2016-11-24 University Of Maryland, Baltimore Treatment agents for inhibiting hiv and cancer in hiv infected patients
WO2016184963A1 (en) 2015-05-19 2016-11-24 Innavirvax Treatment of hiv-infected individuals
WO2016184973A1 (en) 2015-05-19 2016-11-24 Innavirvax Treatment of hiv-infected individuals
WO2016184962A1 (en) 2015-05-19 2016-11-24 Innavirvax Treatment of hiv-infected individuals
CN108025048B (zh) 2015-05-20 2022-10-25 博德研究所 共有的新抗原
CN108135168B (zh) 2015-05-21 2021-07-20 凯莫森特里克斯股份有限公司 Ccr2调节剂
WO2016191363A1 (en) 2015-05-22 2016-12-01 Aphios Corporation Combination hiv therapeutic
WO2016189011A1 (en) 2015-05-26 2016-12-01 F. Hoffmann-La Roche Ag Heterocyclic estrogen receptor modulators and uses thereof
CN104892648A (zh) 2015-05-27 2015-09-09 天津工业大学 一种负载抗肿瘤药物的靶向金属有机骨架的制备及用途
US20180164317A1 (en) 2015-05-28 2018-06-14 Bayer Pharma Aktiengesellschaft Method for stratification of melanoma patients by determination of oxygen consumption, ppargc1a, ppargc1b and mitf levels
WO2016196471A1 (en) 2015-06-02 2016-12-08 Cooper Human Systems Llc Methods and compositions for treatment of hiv infection
JP6721252B2 (ja) 2015-06-05 2020-07-08 ミラゲン セラピューティクス， インコーポレイテッド 皮膚Ｔ細胞リンパ腫（ＣＴＣＬ）を処置するためのｍｉＲ−１５５阻害剤
AU2016270373A1 (en) 2015-06-05 2018-01-04 Vertex Pharmaceuticals Incorporated Triazoles for the treatment of demyelinating diseases
US10370339B2 (en) 2015-06-08 2019-08-06 Bayer Pharma Aktiengesellschaft N-Methylbenzimidazoles as mIDH1 inhibitors
AU2016276963C1 (en) 2015-06-12 2021-08-05 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
CN112125929A (zh) 2015-06-15 2020-12-25 杭州多禧生物科技有限公司 用于偶联的亲水链接体
US10975112B2 (en) 2015-06-16 2021-04-13 Hangzhou Dac Biotech Co., Ltd. Linkers for conjugation of cell-binding molecules
WO2016205566A1 (en) 2015-06-16 2016-12-22 The Regents Of The University Of California Fzd7 specific antibodies and vaccines to treat cancer and control stem cell function
WO2016205551A2 (en) 2015-06-16 2016-12-22 The Regents Of The University Of California Fzd7 specific antibodies and vaccines to treat cancer and control stem cell function
WO2016202758A1 (en) 2015-06-18 2016-12-22 Bayer Pharma Aktiengesellschaft Substituted 2-(1h-pyrazol-1-yl)-1h-benzimidazole compounds
WO2016202756A1 (en) 2015-06-18 2016-12-22 Bayer Pharma Aktiengesellschaft Substituted 2-(1h-pyrazol-1-yl)-1h-benzimidazole compounds
WO2016205695A1 (en) 2015-06-19 2016-12-22 Faller Douglas V Methods and compositions for treating herpesvirus induced conditions
CN116726190A (zh) 2015-06-20 2023-09-12 杭州多禧生物科技有限公司 澳瑞他汀类似物及其与细胞结合分子的共轭偶联物
PE20180610A1 (es) 2015-06-22 2018-04-09 Bayer Pharma AG CONJUGADOS DE LIGADOR-PRINCIPIO ACTIVO (ADCs) Y CONJUGADOS DE LIGADOR-PROFARMACO (APDCs) CON GRUPOS ENZIMATICAMENTE ESCINDIBLES
JP2018525334A (ja) 2015-06-23 2018-09-06 バイエル ファーマ アクチエンゲゼルシャフト キネシンスピンドルタンパク質（ｋｓｐ）阻害剤の抗ｔｗｅａｋｒ抗体との抗体薬物複合体
CA2990398A1 (en) 2015-06-23 2016-12-29 Bayer Pharma Aktiengesellschaft Antibody drug conjugates of kinesin spindel protein (ksp) inhibitors with anti-cd123-antibodies
CN107921288A (zh) 2015-06-23 2018-04-17 拜耳医药股份有限公司 Ksp抑制剂的靶向缀合物
EP3313388A4 (en) 2015-06-24 2019-05-15 Duke University CHEMICAL MODULATORS OF SIGNALING PATHS AND THERAPEUTIC USE
WO2016210247A1 (en) 2015-06-24 2016-12-29 Duke University New methods of use for an anti-diarrhea agent
KR20240090657A (ko) 2015-06-29 2024-06-21 아브락시스 바이오사이언스, 엘엘씨 나노입자 mTOR 억제제 조합 요법을 사용하여 고형 종양을 치료하는 방법
MX2017015357A (es) 2015-06-29 2018-03-16 Merck Patent Gmbh Compuestos inhibidores de serina/treonina-proteina cinasa (tbk)/inhibidor de cinasa de factor nuclear kappa-b subunidad epsilon (ikk-epsilon) y usos de los mismos.
EP3313409A4 (en) 2015-06-29 2018-12-26 Abraxis BioScience, LLC Methods of treating hematological malignancy using nanoparticle mtor inhibitor combination therapy
AU2016285597A1 (en) 2015-06-29 2018-01-18 Syndax Pharmaceuticals, Inc. Combination of HDAC inhibitor and anti-PD-L1 antibody for treatment of cancer
EP3316871A4 (en) 2015-06-30 2019-02-20 The Trustees of Columbia University in the City of New York TALKED COMPOSITION AND USES THEREOF
TW201708210A (zh) 2015-06-30 2017-03-01 葛蘭素史克智慧財產（第二）有限公司 Ｚｅｓｔｅ同源物２增強子之抑制劑
JP6700321B2 (ja) 2015-07-04 2020-05-27 ハンジョウ ディーエーシー バイオテック シーオー．，エルティディ．Ｈａｎｇｚｈｏｕ Ｄａｃ Ｂｉｏｔｅｃｈ Ｃｏ．，Ｌｔｄ． 細胞結合分子の特異的共役体
CN107949557B (zh) 2015-07-07 2021-11-02 德国癌症研究公共权益基金会 作为mIDH1抑制剂的2-芳基-和2-芳烷基-苯并咪唑类
US20180371550A1 (en) 2015-07-08 2018-12-27 Children's Hospital Medical Center Loss of transcriptional fidelity leads to immunotherapy resistance in cancers
WO2017007987A1 (en) 2015-07-09 2017-01-12 Merck Patent Gmbh Pyrimidine derivatives as btk inhibitors and uses thereof
WO2017005711A1 (de) 2015-07-09 2017-01-12 Bayer Pharma Aktiengesellschaft Phosphor- und schwefel-substituierte benzodiazepin-derivate
US10292961B2 (en) 2015-07-15 2019-05-21 Hangzhou Dac Biotech Co., Ltd. Disulfur bridge linkers for conjugation of a cell-binding molecule
US9839687B2 (en) 2015-07-15 2017-12-12 Suzhou M-Conj Biotech Co., Ltd. Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
JP6824954B2 (ja) 2015-07-16 2021-02-03 ドイチェス クレープスフォルシュングスツェントルム シュティフトゥング デス エッフェントリッヒェン レヒツ ｍＩＤＨ１阻害剤としての５−ヒドロキシアルキルベンズイミダゾール
GB201512869D0 (en) 2015-07-21 2015-09-02 Almac Diagnostics Ltd Gene signature for minute therapies
EP3121166A1 (en) 2015-07-21 2017-01-25 Bayer Pharma Aktiengesellschaft Fused imidazoles as midh1 inhibitors
WO2017019767A1 (en) 2015-07-27 2017-02-02 Myosotis, Llc Inhibition of CXCL12 in Cancer Immunotherapy
TW201718495A (zh) 2015-07-28 2017-06-01 貝塔貓製藥股份有限公司 蒽-9, 10-二酮二肟化合物前驅藥及其用途
WO2017019897A1 (en) 2015-07-29 2017-02-02 Novartis Ag Combination therapies comprising antibody molecules to tim-3
PL3330267T3 (pl) 2015-07-29 2022-04-04 Shionogi&Co., Ltd. Sól pochodnej chinazoliny lub jej kryształ oraz sposób wytwarzania soli pochodnej chinazoliny lub jej kryształu
EP3317301B1 (en) 2015-07-29 2021-04-07 Novartis AG Combination therapies comprising antibody molecules to lag-3
CN114272371A (zh) 2015-07-29 2022-04-05 诺华股份有限公司 包含抗pd-1抗体分子的联合疗法
ES2939084T3 (es) 2015-07-29 2023-04-18 Onk Therapeutics Ltd Células asesinas naturales y líneas de células asesinas naturales modificadas que tienen citotoxicidad aumentada
EP3124609A1 (en) 2015-07-29 2017-02-01 IFOM Fondazione Istituto Firc di Oncologia Molecolare Therapeutics oligonucleotides
CN108135933B (zh) 2015-07-31 2022-04-29 脉管生物生长有限公司 含有活动精子结构域的蛋白质2和癌症
KR20180035894A (ko) 2015-08-03 2018-04-06 콰드리가 바이오사이언시스 인코포레이티드 화학치료제로서의 베타-치환된 베타-아미노산 및 유사체 및 이들의 용도
WO2017021348A1 (en) 2015-08-05 2017-02-09 Bayer Pharma Aktiengesellschaft 1h-pyrrol-3-amines
WO2017023994A1 (en) 2015-08-06 2017-02-09 Yale University Small molecule based antibody-recruiting compounds for cancer treatment
WO2017027379A1 (en) 2015-08-07 2017-02-16 Thomas Helledays Stiftelse För Medicinsk Forskning Method for diagnosisng cancer or cancer-associated thrombosis by measuring levels of h3cit in plasma
WO2017025493A1 (en) 2015-08-12 2017-02-16 Bayer Pharma Aktiengesellschaft Quinoline ezh2 inhibitors
WO2017027760A1 (en) 2015-08-12 2017-02-16 North Carolina State University Platelet membrane-coated drug delivery system
EP3133165A1 (en) 2015-08-17 2017-02-22 F. Hoffmann-La Roche AG Methods for personalizing patient cancer therapy with anti angiogenic compounds
US10633399B2 (en) 2015-08-17 2020-04-28 Channel Therapeutics, Inc. Functionalized aminobenzoboroxoles
GB201514756D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compound and method of use
WO2017034234A1 (ko) 2015-08-21 2017-03-02 서울대학교 산학협력단 Hdac 억제제 내성을 갖는 암 치료용 복합제제
US20170056352A1 (en) 2015-08-25 2017-03-02 Rgenix, Inc. PHARMACEUTICALLY ACCEPTABLE SALTS OF beta-GUANIDINOPROPIONIC ACID WITH IMPROVED PROPERTIES AND USES THEREOF
AU2016312508A1 (en) 2015-08-26 2018-02-15 Gilead Sciences, Inc. Deuterated toll-like receptor modulators
WO2017035453A1 (en) 2015-08-26 2017-03-02 The Johns Hopkins University Compositions and methods for treating solid tumors
US11096934B2 (en) 2015-09-01 2021-08-24 The Broad Institute, Inc. Compounds and methods useful for treating or preventing hematological cancers
US10588985B2 (en) 2015-09-02 2020-03-17 Wayne State University Compositions and methods relating to RAD6 inhibition
KR102631377B1 (ko) 2015-09-02 2024-01-29 신닥스 파마슈티컬스, 인크. 조합 요법을 위한 환자의 선별
US20170114098A1 (en) 2015-09-03 2017-04-27 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
DE102015012050A1 (de) 2015-09-15 2017-03-16 Merck Patent Gmbh Verbindungen als ASIC-Inhibitoren und deren Verwendungen
DE102015012049A1 (de) 2015-09-15 2017-03-16 Merck Patent Gmbh Verbindungen als ASIC-Inhibitoren und deren Verwendungen
ES2980858T3 (es) 2015-09-15 2024-10-03 Stichting Radboud Univ Medisch Centrum Método mejorado para la expansión ex vivo de HSPC CD34+ en células NK usando un antagonista del receptor de aril hidrocarburos
JP7083750B2 (ja) 2015-09-18 2022-06-13 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｉｒａｋ阻害剤としてのヘテロアリール化合物及びその使用
NZ739676A (en) 2015-09-18 2022-02-25 Merck Patent Gmbh Heteroaryl compounds as irak inhibitors and uses thereof
AU2016324493A1 (en) 2015-09-20 2018-05-10 Air Cross, Inc. Ozonolysis for activation of compounds and degradation of ozone
EP3353179B1 (en) 2015-09-21 2022-02-09 Plexxikon Inc. Heterocyclic compounds and uses thereof
AU2016328683A1 (en) 2015-09-21 2018-05-10 Ifom Fondazione Istituto Firc Di Oncologia Molecolare New therapeutic strategies against blood cancer
WO2017053823A1 (en) 2015-09-25 2017-03-30 Pharmacyclics Llc Treatment using hdac inhibitors and immunotherapy
WO2017054739A1 (zh) 2015-09-29 2017-04-06 康朴生物医药技术（上海）有限公司 一种药物组合物及其应用
CA2999516A1 (en) 2015-09-30 2017-04-06 Gilead Sciences, Inc. Compounds and combinations for the treatment of hiv
ES2900482T3 (es) 2015-10-01 2022-03-17 Gilead Sciences Inc Combinación de un inhibidor de Btk y un inhibidor de punto de control para el tratamiento del cáncer
WO2017055316A1 (en) 2015-10-01 2017-04-06 Bayer Pharma Aktiengesellschaft Amido-substituted azole compounds
WO2017055313A1 (en) 2015-10-01 2017-04-06 Bayer Pharma Aktiengesellschaft Amido-substituted azole compounds
US10544156B2 (en) 2015-10-02 2020-01-28 Pierre Fabre Medicament Hemi-synthetic trilobine analogs for use as a drug
CA3000746A1 (en) 2015-10-02 2017-04-06 Gilead Sciences, Inc. Combinations of the btk inhibitor gs-4059 with inhibitors selected from a jak, ask1, brd and/or mmp9 inhibitor to treat cancer, allergic disorders, autoimmune diseases or inflammatory diseases
TWI737635B (zh) 2015-10-09 2021-09-01 德商百靈佳殷格翰國際股份有限公司 作為mdm2－p53抑制劑之新穎螺﹝3h－吲哚－3，2´－吡咯啶﹞－2（1h）－酮化合物及其衍生物
WO2017060322A2 (en) 2015-10-10 2017-04-13 Bayer Pharma Aktiengesellschaft Ptefb-inhibitor-adc
WO2017063966A1 (en) 2015-10-13 2017-04-20 Bayer Pharma Aktiengesellschaft Substituted 2-(1h-pyrazol-1-yl)-benzothiazole compounds
CN105288648B (zh) 2015-10-14 2018-11-06 东南大学 一种亲水性药物的磷脂化合物、其药物组合物及应用
MY201637A (en) 2015-10-15 2024-03-06 Celularity Inc Natural killer cells and ilc3 cells and uses thereof
WO2017063959A1 (de) 2015-10-15 2017-04-20 Bayer Pharma Aktiengesellschaft N-sulfoximinophenyl-substituierte benzodiazepin-derivate als bet-proteininhibitoren
WO2017070198A1 (en) 2015-10-19 2017-04-27 Dana-Farber Cancer Institute, Inc. Polymerase q as a target in hr-deficient cancers
TWI806822B (zh) 2015-10-23 2023-07-01 日商第一三共股份有限公司 製備治療癌症之醫藥組成物之用途
CN108135884A (zh) 2015-10-23 2018-06-08 第三共株式会社 用于治疗aml的药物组合物和治疗有此需要的对象中的aml的方法
US20170115275A1 (en) 2015-10-23 2017-04-27 Arizona Board Of Regents On Behalf Of Arizona State University Engineered substrates for high-throughput generation of 3d models of tumor dormancy, relapse and micrometastases for phenotype specific drug discovery and development
WO2017074788A1 (en) 2015-10-27 2017-05-04 The Broad Institute Inc. Compositions and methods for targeting cancer-specific sequence variations
WO2017075451A1 (en) 2015-10-28 2017-05-04 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1
WO2017075465A1 (en) 2015-10-28 2017-05-04 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3
EP3368689B1 (en) 2015-10-28 2020-06-17 The Broad Institute, Inc. Composition for modulating immune responses by use of immune cell gene signature
CA3004138A1 (en) 2015-11-03 2017-05-11 Janssen Biotech, Inc. Antibodies specifically binding pd-1 and tim-3 and their uses
CA3004530A1 (en) 2015-11-07 2017-05-11 Multivir Inc. Methods and compositions comprising tumor suppressor gene therapy and immune checkpoint blockade for the treatment of cancer
CN105457038A (zh) 2015-11-09 2016-04-06 东南大学 一种速释型药物磷脂化合物及其药物组合物
BR112018009361A8 (pt) 2015-11-10 2019-02-26 Univ Yale composições e métodos para o tratamento de doenças autoimunes e de câncer
PT3373959T (pt) 2015-11-12 2022-08-09 Hookipa Biotech Gmbh Partículas de arenavírus como vacinas contra o cancro
JP6931329B2 (ja) 2015-11-18 2021-09-01 中外製薬株式会社 免疫抑制機能を有する細胞に対するｔ細胞リダイレクト抗原結合分子を用いた併用療法
TWI724056B (zh) 2015-11-19 2021-04-11 美商卡默森屈有限公司 Ｃｘｃｒ２抑制劑
TWI734715B (zh) 2015-11-19 2021-08-01 美商卡默森屈有限公司 趨化因子受體調節劑
US10857156B2 (en) 2015-11-20 2020-12-08 Senhwa Biosciences, Inc. Combination therapy of tetracyclic quinolone analogs for treating cancer
WO2017091777A1 (en) 2015-11-24 2017-06-01 Vijay Krishnan Novel healthcare delivery, treatment, and payment model for specialty drugs
AU2016363770A1 (en) 2015-12-01 2018-06-28 Genmab B.V. Anti-DR5 antibodies and methods of use thereof
US10654818B2 (en) 2015-12-03 2020-05-19 Bayer Pharma Aktiengesellschaft Furane derivatives as inhibitors of ATAD2
JP2018537128A (ja) 2015-12-03 2018-12-20 アルフレッド ヘルス 骨髄腫の治療または進行のモニタリング
US10722529B2 (en) 2015-12-03 2020-07-28 Temple University—Of the Commonwealth System of Higher Education Modulation of NAD+ metabolic pathways for treatment of disease
UA122079C2 (uk) 2015-12-04 2020-09-10 Бьорінгер Інгельхайм Інтернаціональ Гмбх Поліпептид, що специфічно зв'язується з lrp5 і lrp6
CN106821965A (zh) 2015-12-04 2017-06-13 中国科学院大连化学物理研究所 一种维甲酸多药共递送纳米粒溶液及其制备和应用
AU2016367306B2 (en) 2015-12-09 2021-04-22 Medizinische Universität Wien Monomaleimide-functionalized platinum compounds for cancer therapy
US10969392B2 (en) 2015-12-10 2021-04-06 Vanderbilt University Methods and systems for predicting response to immunotherapies for treatment of cancer
CU20180062A7 (es) 2015-12-15 2018-08-06 Gilead Sciences Inc Anticuerpos neutralizadores del virus de inmunodeficiencia humana
MA43576A (fr) 2015-12-16 2018-11-14 Merck Sharp & Dohme Anticorps anti-lag3 et fragments de fixation à l'antigène
WO2017102649A1 (en) 2015-12-16 2017-06-22 Bayer Pharma Aktiengesellschaft Hetero-1,5,6,7-tetrahydro-4h-indol-4-ones
ES2986067T3 (es) 2015-12-17 2024-11-08 Novartis Ag Moléculas de anticuerpos frente a PD-1 y usos de las mismas
WO2017106556A1 (en) 2015-12-17 2017-06-22 Gilead Sciences, Inc. Tank-binding kinase inhibitor compounds
EP3889145B1 (en) 2015-12-17 2024-02-21 Merck Patent GmbH 8-cyano-5-piperidino-quinolines as tlr7/8 antagonists and their uses for treating immune disorders
US10894784B2 (en) 2015-12-18 2021-01-19 Bayer Pharma Aktiengesellschaft Heteroarylbenzimidazole compounds
AU2016370813A1 (en) 2015-12-18 2018-06-28 Novartis Ag Antibodies targeting CD32b and methods of use thereof
EP3393458A4 (en) 2015-12-22 2019-08-14 GlaxoSmithKline LLC METHOD OF USE OF A CLASS IIA HDAC HEMMER
JP2019505579A (ja) 2015-12-23 2019-02-28 ムーンショット ファーマ エルエルシー 免疫応答を誘導するための方法
US20190290759A1 (en) 2015-12-28 2019-09-26 Syndax Pharmaceuticals, Inc. Combination of hdac inhibitor and anti-pd-l1 antibody for treatment of ovarian cancer
WO2017117418A1 (en) 2015-12-30 2017-07-06 Anthrogenesis Corporation T lymphocyte production methods and t lymphocytes produced thereby
US10189797B2 (en) 2015-12-30 2019-01-29 Duke University Chemical modulators of immune checkpoints and therapeutic use
EP3400009A2 (en) 2016-01-05 2018-11-14 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Combination of histone deacetylase inhibitor and immunotherapy
CN109312309B (zh) 2016-01-08 2024-04-02 雷普利穆内有限公司 工程化的病毒
JP7025022B2 (ja) 2016-01-11 2022-02-24 ザ ロックフェラー ユニバーシティー 骨髄系由来抑制細胞関連障害の治療のための方法
WO2017121684A1 (en) 2016-01-14 2017-07-20 Bayer Pharma Aktiengesellschaft 5-substituted 2-(morpholin-4-yl)-1,7-naphthyridines
MX2018008771A (es) 2016-01-19 2018-11-09 Janssen Pharmaceutica Nv Formulaciones/composiciones que comprenden un inhibidor de btk.
EP3405790B1 (en) 2016-01-19 2023-06-28 Celgene Corporation Transgenic mouse expressing human cereblon
US10973843B2 (en) 2016-01-27 2021-04-13 University Of Maryland, Baltimore Method for monitoring cancer and for regulation of semaphorin 4D to improve cancer immunotherapy regimens
AU2017211383A1 (en) 2016-01-28 2018-08-16 Indiana University Research & Technology Corporation Use of histone deacetylase inhibitors for enhancing immunotherapies
DK3408407T3 (da) 2016-01-29 2021-02-08 Epigenomics Ag Fremgangsmåder til påvisning af cpg-methylering af tumorafledt dna i blodprøver
GB201601773D0 (en) 2016-02-01 2016-03-16 Renishaw Plc Method
US20190382839A1 (en) 2016-02-01 2019-12-19 Bayer Pharma Aktiengesellschaft Copanlisib biomarkers
WO2017134000A1 (en) 2016-02-01 2017-08-10 Bayer Pharma Aktiengesellschaft Copanlisib biomarkers
WO2017136342A1 (en) 2016-02-02 2017-08-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Fulvestrant for inducing immune-mediated cytotoxic lysis of cancer cells
WO2017134116A1 (en) 2016-02-02 2017-08-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for enhancing cd8+ t cell-dependent immune responses in subjects suffering from cancer
EP3411074A4 (en) 2016-02-04 2019-09-04 Suzhou M-conj Biotech Co., Ltd. SPECIFIC CONJUGATION LINKERS, SPECIFIC IMMUNOCONJUGATES THEREOF, METHOD FOR THE PRODUCTION AND USE THEREOF OF SUCH CONJUGATES
TW201733591A (zh) 2016-02-05 2017-10-01 拜耳製藥公司 用於癌症病人分級及癌症治療之化合物、組合物及方法
EP3413885A4 (en) 2016-02-08 2019-09-18 Beyondspring Pharmaceuticals, Inc. COMPOSITIONS WITH TUCARESOL OR ITS ANALOG
EP3413914A4 (en) 2016-02-10 2019-10-16 Immunomedics, Inc. COMBINATION OF ABCG2 INHIBITORS WITH SACITUZUMAB GOVITECAN (IMMU-132) TO OVERCOME THE RESISTANCE TO SN-38 IN TROP-2-EXPRESSIVE CANCER
US11311540B2 (en) 2016-02-17 2022-04-26 Acetylon Pharmaceuticals, Inc. Increasing expression of interferon regulated genes with combinations of histone deacetylase inhibitors and immunomodulatory drugs
WO2017143035A2 (en) 2016-02-17 2017-08-24 The Penn State Research Foundation Method and therapeutic use of pign and other genes or genes products that pign interacts with for prognosis and treatment of hematological neoplasias
WO2017144548A1 (en) 2016-02-22 2017-08-31 Onxeo Combination therapies comprising immuno-oncology agents and doxorubicin-loaded poly(cyanoacrylate) nanoparticles
JP2019511919A (ja) 2016-02-23 2019-05-09 ブローディ，チャヤ がん幹細胞の作製およびその使用
US20170247690A1 (en) 2016-02-25 2017-08-31 Agenovir Corporation Oncoviral treatment with nuclease and chemotherapeutic
JP2019510752A (ja) 2016-03-04 2019-04-18 ギリアード サイエンシーズ， インコーポレイテッド オートタキシン阻害剤の組成物及び合剤
WO2017148995A1 (en) 2016-03-04 2017-09-08 Bayer Pharma Aktiengesellschaft 1-(pyrimidin-2-yl)-1h-indazoles having bub1 kinase inhibiting activity
US10143746B2 (en) 2016-03-04 2018-12-04 Bristol-Myers Squibb Company Immunomodulators
US11357849B2 (en) 2016-03-07 2022-06-14 Musc Foundation For Research Development Anti-nucleolin antibodies
WO2017156147A1 (en) 2016-03-08 2017-09-14 The Board Of Regents For Oklahoma State University Office Of Intellectual Property Management Technology Development Center Immune boosting dietary compounds for disease control and prevention
EP3426657B1 (en) 2016-03-08 2022-07-13 Bayer Pharma Aktiengesellschaft 2 amino n [7 methoxy 2, 3-dihydroimidazo-[1, 2-c]quinazolin-5-yl]pyrimidine 5 carboxamides
WO2017160761A2 (en) 2016-03-14 2017-09-21 Kiromic, Inc. Compositions and methods for treating cancers
WO2017157418A1 (en) 2016-03-15 2017-09-21 Bayer Pharma Aktiengesellschaft Combination of mknk1-inhibitors
WO2017160717A2 (en) 2016-03-15 2017-09-21 Memorial Sloan Kettering Cancer Center Method of treating diseases using kinase modulators
US20170268001A1 (en) 2016-03-16 2017-09-21 The University Of Chicago Rnas with tumor radio/chemo-sensitizing and immunomodulatory properties and methods of their preparation and application
EP3219329A1 (en) 2016-03-17 2017-09-20 Bayer Pharma Aktiengesellschaft Combinations of copanlisib
WO2017157991A1 (en) 2016-03-18 2017-09-21 Bayer Pharma Aktiengesellschaft 1-alkyl-pyrazoles and -indazoles as bub1 inhibitors for the treatment of hyperproliferative diseases
WO2017157992A1 (en) 2016-03-18 2017-09-21 Bayer Pharma Aktiengesellschaft Annulated pyrazoles as bub1 kinase inhibitors for treating proliferative disorders
WO2017161331A1 (en) 2016-03-18 2017-09-21 Procept Biorobotics Corporation Minimally invasive methods and systems for hemostasis in a bleeding closed tissue volume
US20170273926A1 (en) 2016-03-24 2017-09-28 Orbus Therapeutics, Inc. Compositions and methods for use of eflornithine and derivatives and analogs thereof to treat cancers, including gliomas
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
CN105949114A (zh) 2016-06-27 2016-09-21 山东川成医药股份有限公司 一种西达本胺的合成方法
US20190282541A1 (en) 2016-07-20 2019-09-19 Eisai R&D Management Co., Ltd. Use of eribulin and histone deacetylase inhibitors in the treatment of cancer
CN106866571B (zh) 2017-01-20 2018-06-29 中国药科大学 杂环脲类化合物及其药物组合物和应用
ES2899372T3 (es) 2017-02-13 2022-03-11 Kangpu Biopharmaceuticals Ltd Combinación de tratamiento del cáncer de próstata, composición farmacéutica y método de tratamiento
CN106916101B (zh) 2017-02-15 2020-05-01 聚缘（上海）生物科技有限公司 Nampt/hdac双靶点抑制剂及其制备方法
CN107011238B (zh) 2017-03-14 2020-05-01 北京化工大学 一类组蛋白去乙酰化酶抑制剂及其制备方法和用途
WO2018218137A1 (en) 2017-05-25 2018-11-29 Leidos, Inc. Pd-1 and ctla-4 dual inhibitor peptides
US20190046513A1 (en) 2017-08-10 2019-02-14 Huya Bioscience International, Llc Combination therapies of hdac inhibitors and tubulin inhibitors

Similar Documents

Publication Publication Date Title
JP2019518741A5 (OSRAM)
JP7190549B2 (ja) Ｈｄａｃ阻害剤とｐｄ－１阻害剤との組み合わせ療法
JP7190548B2 (ja) Ｈｄａｃ阻害剤とｐｄ－ｌ１阻害剤との組み合わせ療法
RU2020114632A (ru) Терапевтические способы, относящиеся к ингибиторам hsp90
JP2021501145A5 (OSRAM)
KR102281961B1 (ko) 면역 조절제를 함유하는 항종양제 및 항종양 효과 증강제
RU2017112048A (ru) Синергистические комбинации ауристана
ES2946472T3 (es) Agente antitumoral y potenciador del efecto antitumoral
JP2016514148A (ja) 抗ｃｄ３８抗体およびカーフィルゾミブを含む組成物
CA2939464A1 (en) Use of anti-ccr5 antibodies in graft versus host disease
TW202102216A (zh) 抗腫瘤組合物
US20110281813A1 (en) Method of treating c-kit positive relapsed acute myeloid leukemia
JPWO2020011724A5 (OSRAM)
CN120936360A (zh) 包括心脏耐受性hdac抑制剂的方法和组合物
KR20210060465A (ko) 아실티오우레아 화합물과 아비라테론의 병용 요법
JPWO2020249528A5 (OSRAM)
BR122024004327A2 (pt) Combinação, composição farmacêutica, kit, composto, uso de um inibidor da histona desacetilase (inibidor de hdac) e uso de um composto
TH1901007379A (th) ตัวยับยั้ง kras g12c และวิธีการใช้สิ่งดังกล่าว
RU2017133297A (ru) Противоопухолевые комбинации с ингибиторами mtor, герцептином и/или hki-272
BR122024004326A2 (pt) Combinação, composição farmacêutica, kit, composto, uso de um inibidor da histona desacetilase (inibidor de hdac) e uso de um composto